All In Biotech

Free tool

FAERS Monitor: Gavreto

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214701 or its brand name (Gavreto, Pralsetinib). Reports on generic versions are filed under their own applications.

Reports

1,824

Serious

1,139

62% of reports

Hospitalization

544

Death reported

259

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product prescribing issue194
  • death152
  • fatigue126
  • off label use120
  • asthenia117
  • anaemia99
  • diarrhoea96
  • hypertension96
  • disease progression91
  • blood pressure increased90
  • constipation90
  • white blood cell count decreased85
  • pyrexia81
  • pneumonia77
  • platelet count decreased56

Reports by year received

View as table
YearReports
202048
2021467
2022275
2023179
2024370
2025323
2026162

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,335 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product prescribing issueSignal194103.690.619,456
white blood cell count decreasedSignal859.07.4603
disease progressionSignal918.97.3631
blood pressure increasedSignal906.85.6442
platelet count decreasedSignal566.14.7233
anaemiaSignal996.04.9410
hypertensionSignal965.24.3327
constipationSignal904.83.9266
astheniaSignal1173.63.0220
pneumoniaSignal772.72.285
pyrexiaSignal812.72.286
deathSignal1522.01.782
fatigue1261.91.652
diarrhoea961.71.429
off label use1201.61.326

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.